Sinopharm s Wuhan Institute of Biological Products has recently successfully separated monkeypox virus strains from clinical samples of infected patients to help scientific research into the epidemic prevention and control of monkeypox.
Efficacy of Sinopharm s COVID-19 vaccines proved again in new trials cgtn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cgtn.com Daily Mail and Mail on Sunday newspapers.
Sinovac to double CoronaVac output by next month By ZHENG YIRAN | China Daily | Updated: 2021-01-20 09:34 Share An employee of Sinovac Biotech handles boxes containing COVID-19 vaccines. [Photo/Xinhua]
Sinovac Biotech Ltd will double annual capacity of its CoronaVac vaccine production to 1 billion doses by next month, said its top official.
The proposed plant expansion is an attempt to meet surging demand for COVID-19 vaccines at home and abroad. The yearly output of our first production line at the company s base in Daxing district of Beijing has reached 500 million doses. After the second production line starts operations in February, we will be able to produce 1 billion doses of vaccine every year, said Yin Weidong, chairman of Sinovac, a Beijing-based, Nasdaq-listed, private-sector company.